{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:44:48Z","timestamp":1767033888037,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.pupt.2023.102232","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T21:48:45Z","timestamp":1689198525000},"page":"102232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3441-8264","authenticated-orcid":false,"given":"D.","family":"Lachant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Minkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mogri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Zolty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.pupt.2023.102232_bib1","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1161\/CIRCULATIONAHA.114.006974","article-title":"Advances in therapeutic interventions for patients with pulmonary arterial hypertension","volume":"130","author":"Humbert","year":"2014","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.pupt.2023.102232_bib2","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMra2000348","article-title":"Pulmonary arterial hypertension","volume":"385","author":"Hassoun","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"38","key":"10.1016\/j.pupt.2023.102232_bib3","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.pupt.2023.102232_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019898032","article-title":"Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension","volume":"10","author":"Oriaku","year":"2020","journal-title":"Pulm. Circ."},{"issue":"26","key":"10.1016\/j.pupt.2023.102232_bib5","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"year":"2021","series-title":"US Package Insert","author":"UPTRAVI\u00ae (selexipag)","key":"10.1016\/j.pupt.2023.102232_bib6"},{"year":"2019","series-title":"Orenitram (Treprostinil) Extended Release Tablets, US Package Insert","key":"10.1016\/j.pupt.2023.102232_bib7"},{"issue":"6","key":"10.1016\/j.pupt.2023.102232_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial","volume":"201","author":"White","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2023.102232_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.prostaglandins.2015.04.007","article-title":"The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors","volume":"120","author":"Clapp","year":"2015","journal-title":"Prostag. Other Lipid Mediat."},{"key":"10.1016\/j.pupt.2023.102232_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.prostaglandins.2013.07.001","article-title":"A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor","volume":"107","author":"Benyahia","year":"2013","journal-title":"Prostag. Other Lipid Mediat."},{"issue":"1","key":"10.1016\/j.pupt.2023.102232_bib11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcp.2012.03.012","article-title":"Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist","volume":"84","author":"Whittle","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.pupt.2023.102232_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12083","article-title":"Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)","volume":"12","author":"Aldalaan","year":"2022","journal-title":"Pulm. Circ."},{"issue":"1","key":"10.1016\/j.pupt.2023.102232_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1755-5922.12008","article-title":"Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension","volume":"31","author":"Bourge","year":"2013","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.pupt.2023.102232_bib14","article-title":"Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension","volume":"37","author":"Arevalo","year":"2022","journal-title":"Respir. Med. Case Rep."},{"issue":"1","key":"10.1016\/j.pupt.2023.102232_bib15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension","volume":"159","author":"Benza","year":"2021","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.pupt.2023.102232_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020973124","article-title":"Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study","volume":"10","author":"Simonneau","year":"2020","journal-title":"Pulm. Circ."},{"issue":"5","key":"10.1016\/j.pupt.2023.102232_bib17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.pupt.2023.102232_bib18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2213-2600(20)30532-4","article-title":"Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial","volume":"9","author":"Hoeper","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2023.102232_bib19","article-title":"Clinical improvement in patients treated with oral treprostinil: a post hoc analysis of the FREEDOM-EV study","volume":"203","author":"Sahay","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2023.102232_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106744","article-title":"Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension","volume":"193","author":"Khan","year":"2022","journal-title":"Respir. Med."},{"issue":"12","key":"10.1016\/j.pupt.2023.102232_bib21","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1164\/rccm.201602-0274LE","article-title":"Novel analysis of the oral treprostinil combination therapy trial data","volume":"193","author":"White","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2023.102232_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.healun.2022.08.006","article-title":"Contemporary risk scores predict clinical worsening in pulmonary arterial hypertension - an analysis of FREEDOM-EV","author":"Benza","year":"2022","journal-title":"J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:31:45Z","timestamp":1761082305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553923000445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":22,"alternative-id":["S1094553923000445"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102232","relation":{},"ISSN":["1094-5539"],"issn-type":[{"type":"print","value":"1094-5539"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102232","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102232"}}